Drug Profile
BAX 499
Alternative Names: Anti-TFPI aptamer; ARC19499Latest Information Update: 13 Aug 2015
Price :
$50
*
At a glance
- Originator Archemix Corporation
- Developer Baxalta
- Class Antihaemorrhagics; Coagulants; Nucleotide aptamers
- Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haemophilia
Most Recent Events
- 27 Jul 2011 Interim pharmacodynamics data from a preclinical study in Haemophilia released by Baxter International
- 21 Nov 2010 Baxter International enters into a definitive agreement to acquire all of Archemix's haemophilia-related assets
- 31 Aug 2010 Phase-I clinical trials in Haemophilia in United Kingdom (SC)